Primary chemotherapy in resectable oral cavity squamous cell cancer

A randomized controlled trial

Lisa Licitra, Cesare Grandi, Marco Guzzo, Luigi Mariani, Salvatore Lo Vullo, Francesca Valvo, Pasquale Quattrone, Pinuccia Valagussa, Gianni Bonadonna, Roberto Molinari, Giulio Cantù

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Purpose: Prognosis of patients with advanced oral cavity cancer is worth improving. Chemotherapy has been reported to be especially active in oral cavity tumors. Here we repeat the results of a randomized, multicenter trial enrolling patients with a resectable, stage T2-T4 (> 3 cm), N0-N2, M0 untreated, squamous cell carcinoma of the oral cavity. Patients and Methods: Patients were randomly assigned to three cycles of cisplatin and fluorouracil followed by surgery (chemotherapy arm) or surgery alone (control arm). In both arms, postoperative radiotherapy was reserved to high-risk patients, and surgery was modulated depending on the tumor's closeness to the mandible. Patients' accrual was opened in 1989 and closed in 1999. It included 195 patients. Results: In the chemotherapy arm, three toxic deaths were recorded. No significant difference in overall survival was found. Five-year overall survival was, for both arms, 55%. Postoperative radiotherapy was administered in 33% of patients in the chemotherapy arm, versus 46% in the control arm. A mandible resection was performed in 52% of patients in the control arm, versus 31% in the chemotherapy arm. Conclusion: The addition of primary chemotherapy to standard surgery was unable to improve survival. However, in this study, primary chemotherapy seemed to play a role in reducing the number of patients who needed to undergo mandibulectomy and/or radiation therapy. Variations in the criteria used to select patients for these treatment options may make it difficult to generalize these results, but there appears to be room for using preoperative chemotherapy to spare demolitive surgery and/or radiation therapy in patients with advanced, resectable oral cavity cancer.

Original languageEnglish
Pages (from-to)327-333
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number2
DOIs
Publication statusPublished - Jan 15 2003

Fingerprint

Squamous Cell Neoplasms
Mouth
Randomized Controlled Trials
Drug Therapy
Arm
Radiotherapy
Mouth Neoplasms
Mandible
Survival
Poisons
Fluorouracil
Cisplatin
Multicenter Studies
Squamous Cell Carcinoma
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Primary chemotherapy in resectable oral cavity squamous cell cancer : A randomized controlled trial. / Licitra, Lisa; Grandi, Cesare; Guzzo, Marco; Mariani, Luigi; Lo Vullo, Salvatore; Valvo, Francesca; Quattrone, Pasquale; Valagussa, Pinuccia; Bonadonna, Gianni; Molinari, Roberto; Cantù, Giulio.

In: Journal of Clinical Oncology, Vol. 21, No. 2, 15.01.2003, p. 327-333.

Research output: Contribution to journalArticle

Licitra, Lisa ; Grandi, Cesare ; Guzzo, Marco ; Mariani, Luigi ; Lo Vullo, Salvatore ; Valvo, Francesca ; Quattrone, Pasquale ; Valagussa, Pinuccia ; Bonadonna, Gianni ; Molinari, Roberto ; Cantù, Giulio. / Primary chemotherapy in resectable oral cavity squamous cell cancer : A randomized controlled trial. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 2. pp. 327-333.
@article{8664b04117154324a9d20e10e01e7b92,
title = "Primary chemotherapy in resectable oral cavity squamous cell cancer: A randomized controlled trial",
abstract = "Purpose: Prognosis of patients with advanced oral cavity cancer is worth improving. Chemotherapy has been reported to be especially active in oral cavity tumors. Here we repeat the results of a randomized, multicenter trial enrolling patients with a resectable, stage T2-T4 (> 3 cm), N0-N2, M0 untreated, squamous cell carcinoma of the oral cavity. Patients and Methods: Patients were randomly assigned to three cycles of cisplatin and fluorouracil followed by surgery (chemotherapy arm) or surgery alone (control arm). In both arms, postoperative radiotherapy was reserved to high-risk patients, and surgery was modulated depending on the tumor's closeness to the mandible. Patients' accrual was opened in 1989 and closed in 1999. It included 195 patients. Results: In the chemotherapy arm, three toxic deaths were recorded. No significant difference in overall survival was found. Five-year overall survival was, for both arms, 55{\%}. Postoperative radiotherapy was administered in 33{\%} of patients in the chemotherapy arm, versus 46{\%} in the control arm. A mandible resection was performed in 52{\%} of patients in the control arm, versus 31{\%} in the chemotherapy arm. Conclusion: The addition of primary chemotherapy to standard surgery was unable to improve survival. However, in this study, primary chemotherapy seemed to play a role in reducing the number of patients who needed to undergo mandibulectomy and/or radiation therapy. Variations in the criteria used to select patients for these treatment options may make it difficult to generalize these results, but there appears to be room for using preoperative chemotherapy to spare demolitive surgery and/or radiation therapy in patients with advanced, resectable oral cavity cancer.",
author = "Lisa Licitra and Cesare Grandi and Marco Guzzo and Luigi Mariani and {Lo Vullo}, Salvatore and Francesca Valvo and Pasquale Quattrone and Pinuccia Valagussa and Gianni Bonadonna and Roberto Molinari and Giulio Cant{\`u}",
year = "2003",
month = "1",
day = "15",
doi = "10.1200/JCO.2003.06.146",
language = "English",
volume = "21",
pages = "327--333",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Primary chemotherapy in resectable oral cavity squamous cell cancer

T2 - A randomized controlled trial

AU - Licitra, Lisa

AU - Grandi, Cesare

AU - Guzzo, Marco

AU - Mariani, Luigi

AU - Lo Vullo, Salvatore

AU - Valvo, Francesca

AU - Quattrone, Pasquale

AU - Valagussa, Pinuccia

AU - Bonadonna, Gianni

AU - Molinari, Roberto

AU - Cantù, Giulio

PY - 2003/1/15

Y1 - 2003/1/15

N2 - Purpose: Prognosis of patients with advanced oral cavity cancer is worth improving. Chemotherapy has been reported to be especially active in oral cavity tumors. Here we repeat the results of a randomized, multicenter trial enrolling patients with a resectable, stage T2-T4 (> 3 cm), N0-N2, M0 untreated, squamous cell carcinoma of the oral cavity. Patients and Methods: Patients were randomly assigned to three cycles of cisplatin and fluorouracil followed by surgery (chemotherapy arm) or surgery alone (control arm). In both arms, postoperative radiotherapy was reserved to high-risk patients, and surgery was modulated depending on the tumor's closeness to the mandible. Patients' accrual was opened in 1989 and closed in 1999. It included 195 patients. Results: In the chemotherapy arm, three toxic deaths were recorded. No significant difference in overall survival was found. Five-year overall survival was, for both arms, 55%. Postoperative radiotherapy was administered in 33% of patients in the chemotherapy arm, versus 46% in the control arm. A mandible resection was performed in 52% of patients in the control arm, versus 31% in the chemotherapy arm. Conclusion: The addition of primary chemotherapy to standard surgery was unable to improve survival. However, in this study, primary chemotherapy seemed to play a role in reducing the number of patients who needed to undergo mandibulectomy and/or radiation therapy. Variations in the criteria used to select patients for these treatment options may make it difficult to generalize these results, but there appears to be room for using preoperative chemotherapy to spare demolitive surgery and/or radiation therapy in patients with advanced, resectable oral cavity cancer.

AB - Purpose: Prognosis of patients with advanced oral cavity cancer is worth improving. Chemotherapy has been reported to be especially active in oral cavity tumors. Here we repeat the results of a randomized, multicenter trial enrolling patients with a resectable, stage T2-T4 (> 3 cm), N0-N2, M0 untreated, squamous cell carcinoma of the oral cavity. Patients and Methods: Patients were randomly assigned to three cycles of cisplatin and fluorouracil followed by surgery (chemotherapy arm) or surgery alone (control arm). In both arms, postoperative radiotherapy was reserved to high-risk patients, and surgery was modulated depending on the tumor's closeness to the mandible. Patients' accrual was opened in 1989 and closed in 1999. It included 195 patients. Results: In the chemotherapy arm, three toxic deaths were recorded. No significant difference in overall survival was found. Five-year overall survival was, for both arms, 55%. Postoperative radiotherapy was administered in 33% of patients in the chemotherapy arm, versus 46% in the control arm. A mandible resection was performed in 52% of patients in the control arm, versus 31% in the chemotherapy arm. Conclusion: The addition of primary chemotherapy to standard surgery was unable to improve survival. However, in this study, primary chemotherapy seemed to play a role in reducing the number of patients who needed to undergo mandibulectomy and/or radiation therapy. Variations in the criteria used to select patients for these treatment options may make it difficult to generalize these results, but there appears to be room for using preoperative chemotherapy to spare demolitive surgery and/or radiation therapy in patients with advanced, resectable oral cavity cancer.

UR - http://www.scopus.com/inward/record.url?scp=0037440210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037440210&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.06.146

DO - 10.1200/JCO.2003.06.146

M3 - Article

VL - 21

SP - 327

EP - 333

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -